Arovella Therapeutics Ltd
ASX:ALA

Watchlist Manager
Arovella Therapeutics Ltd Logo
Arovella Therapeutics Ltd
ASX:ALA
Watchlist
Price: 0.18 AUD -2.7% Market Closed
Market Cap: 190.4m AUD
Have any thoughts about
Arovella Therapeutics Ltd?
Write Note

Arovella Therapeutics Ltd
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Arovella Therapeutics Ltd
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Arovella Therapeutics Ltd
ASX:ALA
Cash & Cash Equivalents
AU$12.7m
CAGR 3-Years
24%
CAGR 5-Years
24%
CAGR 10-Years
N/A
Mayne Pharma Group Ltd
ASX:MYX
Cash & Cash Equivalents
AU$110.1m
CAGR 3-Years
4%
CAGR 5-Years
4%
CAGR 10-Years
N/A
Neuren Pharmaceuticals Ltd
ASX:NEU
Cash & Cash Equivalents
AU$2.6m
CAGR 3-Years
-48%
CAGR 5-Years
-32%
CAGR 10-Years
-19%
Botanix Pharmaceuticals Ltd
ASX:BOT
Cash & Cash Equivalents
AU$79.3m
CAGR 3-Years
54%
CAGR 5-Years
76%
CAGR 10-Years
41%
Probiotec Ltd
ASX:PBP
Cash & Cash Equivalents
AU$12.8m
CAGR 3-Years
-10%
CAGR 5-Years
-8%
CAGR 10-Years
34%
Vita Life Sciences Ltd
ASX:VLS
Cash & Cash Equivalents
AU$27.7m
CAGR 3-Years
21%
CAGR 5-Years
24%
CAGR 10-Years
11%
No Stocks Found

Arovella Therapeutics Ltd
Glance View

Market Cap
189.1m AUD
Industry
Pharmaceuticals

Arovella Therapeutics Ltd. develops pharmaceuticals and distributes medical devices and consumables. The company is headquartered in Perth, Western Australia. The company went IPO on 2002-01-24. The firm focuses on specific disease areas, oncology and conditions that affect the central nervous system. The company is focused on developing therapies to treat human disease. The firm is developing its invariant natural killer T (iNKT) cell therapy platform to treat blood cancers. The firm's OroMist technology develops oral sprays to reformulate pharmaceuticals. Its ZolpiMist oral spray formulation of zolpidem tartrate to treat short-term insomnia. The company is also developing oral sprays to treat migraine headaches, motion sickness, and drug-resistant epilepsy.

ALA Intrinsic Value
0.01 AUD
Overvaluation 96%
Intrinsic Value
Price

See Also

What is Arovella Therapeutics Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
12.7m AUD

Based on the financial report for Jun 30, 2024, Arovella Therapeutics Ltd's Cash & Cash Equivalents amounts to 12.7m AUD.

What is Arovella Therapeutics Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
24%

Over the last year, the Cash & Cash Equivalents growth was 146%. The average annual Cash & Cash Equivalents growth rates for Arovella Therapeutics Ltd have been 24% over the past three years , 24% over the past five years .

Back to Top